Literature DB >> 7612490

Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period.

A J Norton1, J Matthews, V Pappa, J Shamash, S Love, A Z Rohatiner, T A Lister.   

Abstract

BACKGROUND: The histological, immunological and molecular characteristics of mantle cell lymphoma have only recently been delineated. Amongst these characteristics possible factors of prognostic significance include histological growth pattern and blastoid change. PATIENTS AND METHODS: 66 previously untreated cases of mantle cell lymphoma were identified in a retrospective analysis. In 50 cases serial biopsies had been taken during the disease and in 20 cases autopsies had been performed. Besides established factors of prognostic significance, histological growth pattern and blastoid change were examined.
RESULTS: 32 patients achieved an initial complete remission or good partial remission with most cases relapsing or progressing within 2 years. The median survival was 36 months. Factors predicting a poor outcome were high presenting stage, age > 70, low sodium, low albumin and splenomegaly. Blastoid transformation was also a poor prognostic feature, occurring in 32% of cases during life and in 70% of autopsies. Histological growth pattern had no influence on outcome.
CONCLUSION: This study emphasises the difficulties in treating mantle cell lymphoma and the high frequency and prognostic importance of histological transformation.

Entities:  

Mesh:

Year:  1995        PMID: 7612490     DOI: 10.1093/oxfordjournals.annonc.a059154

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  13 in total

1.  Review.

Authors:  Oriol Sendino; Maria Pellisé
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-05

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 3.  Mantle cell lymphoma with a unique pattern of CD5 expression: a case report with review of the literatures.

Authors:  Toshiki Yamada; Naoe Goto; Hisashi Tsurumi; Katsuyoshi Takata; Yasuharu Sato; Tadashi Yoshino; Hisataka Moriwaki; Yusuke Kito; Tamotsu Takeuchi; Hitoshi Iwata
Journal:  Med Mol Morphol       Date:  2013-10-29       Impact factor: 2.309

Review 4.  Mantle cell lymphoma: observation to transplantation.

Authors:  Babak Rajabi; John W Sweetenham
Journal:  Ther Adv Hematol       Date:  2015-02

5.  Blastoid variant of mantle cell lymphoma with lactic acidosis: a case report.

Authors:  Korenori Ohtsubo; Rie Imamura; Ritsuko Seki; Koichi Ohshima; Michitoshi Hashiguchi; Kazuaki Yakushiji; Koji Yoshimoto; Hideaki Ogata; Takashi Okamura; Michio Sata
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

6.  Relapsed mantle cell lymphoma presenting as "sister Mary joseph nodule".

Authors:  Jennifer E Vaughn; Ajay K Gopal
Journal:  Case Rep Med       Date:  2010-04-08

Review 7.  Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature.

Authors:  Kelly Guggisberg; Richard C K Jordan
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-10-31

8.  Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma.

Authors:  Luis Villela; Mauricio García; Rocío Caballero; José R Borbolla-Escoboza; Javier Bolaños-Meade
Journal:  Anticancer Drugs       Date:  2008-10       Impact factor: 2.248

9.  Palatine Tonsils Primary Presentation of Blastoid Variant of Mantle Cell Lymphoma: Case Report.

Authors:  Joana A S Marques; Fátima Ferreira; Daniel P Melo; Margarida Santos; Ricardo P Vaz
Journal:  Head Neck Pathol       Date:  2020-10-22

10.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Authors:  Nitesh P Shirsath; Sonal M Manohar; Kalpana S Joshi
Journal:  Mol Cancer       Date:  2012-10-18       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.